跳转至内容
Merck
CN

D-011

1,3-二硝基甘油 溶液

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C3H6N2O7
化学文摘社编号:
分子量:
182.09
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
200-835-2
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI key

ASIGVDLTBLZXNC-UHFFFAOYSA-N

InChI

1S/C3H6N2O7/c6-3(1-11-4(7)8)2-12-5(9)10/h3,6H,1-2H2

SMILES string

OC(CO[N+]([O-])=O)CO[N+]([O-])=O

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in acetonitrile

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

pharmaceutical (small molecule)

format

single component solution

storage temp.

−20°C

Quality Level

正在寻找类似产品? 访问 产品对比指南

General description

1,3-二硝基甘油是药物血管扩张剂硝酸甘油的主要血浆代谢产物。该经认证的加标溶液®适用于药学研究或临床毒理学中基于色谱或质谱的应用。硝酸甘油用于治疗心脏病,例如心绞痛和慢性心力衰竭。

Legal Information

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

pictograms

FlameExclamation mark

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

存储类别

3 - Flammable liquids

wgk

WGK 2

flash_point_f

35.6 °F - closed cup

flash_point_c

2 °C - closed cup

法规信息

危险化学品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

B Auclair et al.
Pharmaceutical research, 15(4), 614-619 (1998-05-20)
To construct a pharmacokinetic (PK) model and to determine population PK parameters of nitroglycerin (GTN), 1,2-dinitroglycerin (1,2-GDN), and 1,3-dinitroglycerin (1,3-GDN). Data were obtained in thirty healthy volunteers following a single dose of a GTN reservoir transdermal patch. Blood samples were
Magnus Petersson et al.
Clinical physiology and functional imaging, 28(4), 229-234 (2008-04-04)
Patients with chronic heart failure (CHF) often require higher doses of nitroglycerin (glyceryl trinitrate, GTN) than patients with normal cardiac function to achieve a given haemodynamic goal. Two pathways leading to biotransformation of GTN have been characterized; a high-affinity pathway
N Higo et al.
Pharmaceutical research, 9(2), 187-190 (1992-02-01)
The metabolism of nitroglycerin (GTN) to 1,2- and 1,3-glyceryl dinitrate (GDN) by hairless mouse skin in vitro has been measured. In the first set of experiments, GTN was incubated with the 9000g supernatant of fresh, homogenized tissue in the presence
W E Haefeli et al.
Clinical pharmacology and therapeutics, 52(6), 590-596 (1992-12-01)
Independent of the route of nitroglycerin administration, substantial amounts of 1,2-glyceryl dinitrate (1,2-GDN) and 1,3-glyceryl dinitrate (1,3-GDN) metabolites accumulate in humans. Thus far their pharmacologic activity in comparison to nitroglycerin in humans is unknown. To compare the venodilatory potency of
M V Wenzl et al.
British journal of pharmacology, 156(8), 1248-1255 (2009-03-04)
Vascular tolerance to nitroglycerin (GTN) may be caused by impaired GTN bioactivation due to inactivation of mitochondrial aldehyde dehydrogenase (ALDH2). As relaxation to GTN is reduced but still sensitive to ALDH2 inhibitors in ascorbate deficiency, we compared the contribution of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持